Ghaith Hazem S, Gabra Mohamed Diaa, Nafady Mohamed H, Elshawah Hamza Emad, Negida Ahmed, Mushtaq Gohar, Kamal Mohammad Amjad
Faculty of Medicine, Al Azhar University, Cairo, Egypt.
Faculty of Medicine, South Valley University, Qena, Egypt.
Curr Pharm Des. 2022;28(39):3194-3201. doi: 10.2174/1381612827666211210142352.
The current coronavirus disease (COVID-19) pandemic has affected millions of individuals worldwide. Despite extensive research efforts, few therapeutic options currently offer direct clinical benefits for COVID-19 patients. Despite the advances in our understanding of COVID-19, the mortality rates remain significantly high owing to the high viral transmission rates in several countries and the rise of various mutations in the SARS-CoV-2. One currently available and widely used drug that combines both anti-inflammatory and immunomodulatory actions is colchicine, which has been proposed as a possible treatment option for COVID-19. Colchicine still did not get much attention from the medical and scientific communities despite its antiinflammatory and immunomodulatory mechanisms of action and positive preliminary data from early trials. This literature review article provides the scientific rationale for repurposing colchicine as a potential therapy for COVID-19. Further, we summarize colchicine's mechanisms of action and possible roles in COVID-19 patients. Finally, we supplement this review with a summary of the doses, side effects, and early efficacy data from clinical trials to date. Despite the promising early findings from multiple observational and clinical trials about the potential of colchicine in COVID-19, the data from the RECOVERY trial, the largest COVID-19 randomized controlled trial (RCT) in the world, showed no evidence of clinical benefits in mortality, hospital stays, or disease progression (n = 11340 patients). However, multiple other smaller clinical trials showed significant clinical benefits. We conclude that while current evidence does not support the use of colchicine for treating COVID-19, the present body of evidence is heterogeneous and inconclusive. The drug cannot be used in clinical practice or abandoned from clinical research without additional large RCTs providing more robust evidence. At present, the drug should not be used except for investigational purposes.
当前的冠状病毒病(COVID-19)大流行已影响全球数百万人。尽管进行了广泛的研究,但目前几乎没有治疗方法能为COVID-19患者带来直接的临床益处。尽管我们对COVID-19的认识有所进步,但由于一些国家的病毒传播率高以及严重急性呼吸综合征冠状病毒2(SARS-CoV-2)各种突变的出现,死亡率仍然很高。秋水仙碱是一种目前可用且广泛使用的兼具抗炎和免疫调节作用的药物,已被提议作为COVID-19的一种可能治疗选择。尽管秋水仙碱具有抗炎和免疫调节作用机制以及早期试验的阳性初步数据,但它仍未得到医学界和科学界的太多关注。这篇文献综述文章提供了将秋水仙碱重新用作COVID-19潜在疗法的科学依据。此外,我们总结了秋水仙碱的作用机制及其在COVID-19患者中的可能作用。最后,我们补充了迄今为止临床试验的剂量、副作用和早期疗效数据总结。尽管多项观察性和临床试验对秋水仙碱在COVID-19中的潜力有令人鼓舞的早期发现,但世界上最大的COVID-19随机对照试验(RCT)——恢复试验(RECOVERY trial)的数据显示,在死亡率、住院时间或疾病进展方面没有临床益处的证据(n = 11340例患者)。然而,其他多项较小的临床试验显示出显著的临床益处。我们得出结论,虽然目前的证据不支持使用秋水仙碱治疗COVID-19,但目前的证据体系是异质性的且尚无定论。在没有更多大型RCT提供更有力证据的情况下,该药物不能用于临床实践,也不能从临床研究中放弃。目前,除非用于研究目的,否则不应使用该药物。